Second, anti-PD-1/PD-L1 immunotherapy to date was mainly used in unresectable NSCLC patients, but the patients in our cohort were treated with surgery rather than immunotherapy. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.